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Herbal treatment in asthma and COPD –
current evidence
Rebecca Clarke1,2*, Fionnuala T Lundy1,2 and Lorcan McGarvey1,2
Abstract
Asthma and COPD are chronic inflammatory respiratory diseases affecting millions of people worldwide and
increasing in prevalence. Current treatment options for both conditions aim to alleviate symptoms, improve patient
quality of life and prevent disease progression rather than cure the underlying condition itself. Treatments available
to patients include anti-inflammatory therapies, bronchodilators and inhaled corticosteroids. While these treatments
have been deemed effective at alleviating disease symptoms and exacerbations they are not without their
limitations. Overuse of some therapies can induce adverse effects in some patients such as increased risk of
developing pneumonia and cardiac co-morbidities. Along with the risks of side effects not all patients will respond
to the current treatment options and therefore there is an unmet need for additional or alternative treatments for
asthma and COPD. One such area showing good promise in providing an alternative or add-on therapy is that of
phytomedicine. Phytomedicine is defined as a plant-based traditional medical practice that uses various plant
materials in modalities considered both preventive and therapeutic. This review focuses on recent human clinical
trials using plant-based medicines for the treatment of asthma and COPD.
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Introduction
Asthma and chronic obstructive pulmonary disease
(COPD) are common inflammatory obstructive lung dis-
eases which affect many millions of people worldwide
[1–3]. While advances in basic and clinical research have
led to important advances in drug therapy and improve-
ments in care, both conditions are increasing in preva-
lence and are associated with considerable morbidity
and mortality. Although mortality rates for asthma are
relatively low, representing only 1 % of all deaths [4], it
is recognised that in many cases that death could have
been avoided with better routine care; COPD, however,
is the 4th leading cause of death [3] and is projected to
rise to the second most common cause of death world-
wide by 2020. Both conditions cause a significant impair-
ment in quality of life due to impacts on patients’
physical and psychological well-being. In addition, the
social and economic effects are striking; among the most
important are the escalating costs associated with un-
scheduled medical care, hospitalisations and loss of
productivity. Oral and inhaled anti-inflammatory and
bronchodilator medications have formed the basis of
treatment recommendations for both conditions [5, 6]
for the last three decades and despite proven efficacy
there is a recognition that therapeutic options are lim-
ited and not without adverse effects. Thus there is a
need to consider other therapeutic options including
phytomedicines which could be used to complement
existing treatments. In this article we have undertaken a
review of the existing literature of the NCBI PubMed
database, which provides access to the MEDLINE and
NLM databases, using the search terms herbal/plant/
phytomedicine and asthma/COPD. Results were then fil-
tered to only include human clinical trials within the last
10 years.
Current treatments
Asthma is a chronic inflammatory airway disease arising
from a complex interaction between the immune system
and resident cells of the lung to induce the cardinal fea-
tures of bronchial hyper-responsiveness, increased
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mucus production, narrowing of the airways and airway
remodelling. A detailed review of the pathophysiology of
asthma has been covered extensively elsewhere and is
outside the scope of our article [1, 7, 8]. The most im-
portant clinical consequences of this inflammatory
process are the exacerbations of disease causing airway
narrowing and debilitating bouts of shortness of breath,
wheezing, chest tightness and cough. Most asthma treat-
ments aim to control these symptoms and reduce the
frequency of exacerbations and current recommenda-
tions advocate the use of anti-inflammatory treatments,
in particular inhaled corticosteroids (ICS) and broncho-
dilators such as short and long acting β2-adrenergic ago-
nists (LABA; 5). However, there is concern around the
inappropriate use of asthma medications, in particular
the overuse of inhaled corticosteroids in children, which
can effect bone growth, and the inappropriate use of
long acting bronchodilator therapy in isolation which
has been associated with increased morbidity [9]. As well
as the risk of these possible adverse effects not all pa-
tients respond to these treatments and non-adherence to
treatment is common due to issues such as complex
treatment regimens, poor inhalation technique and de-
layed results [10] thus there is an unmet medical need
for complementary therapies for asthma.
COPD presents with similar symptoms to asthma
such as persistent cough, wheezing and shortness of
breath and is caused by an exaggerated inflammatory
response to noxious particles and gases (reviewed in
[2, 11]). Cigarette smoke is the leading cause of
COPD in the developed world [12], while indoor air
pollution due to the burning of biomass fuels is the
biggest risk factor in the developing world [13]. The
inflammatory response induced by these noxious
stimulants can result in emphysema and airway de-
struction caused by factors such as imbalances be-
tween proteinases and anti-proteinases resulting in
increased proteolytic activity, and oxidants and anti-
oxidants which leads to increased oxidative stress
[14, 15]. Treatment for COPD include cessation of
cigarette smoking which in some cases can stop or
slow disease progression, bronchodilators and inhaled
corticosteroids. As in asthma, these therapies are
used to treat the symptoms and control the disease
rather than cure the underlying condition. There is
considerable evidence that inhaled corticosteroids
and bronchodilators improve lung function and qual-
ity of life and reduce disease exacerbations [16, 17].
While such treatments are endorsed in international
treatment guidelines [6] only a small population of
COPD patients show significant improvements and
concerns have emerged regarding the use of inhaled
steroids and higher rates of pneumonia and the
safety of bronchodilator therapy in COPD patients
with cardiac co-morbidities. Therefore more effective
and safe treatments for COPD remain an important
therapeutic objective.
Review
A review of phytomedicine in the treatment of asthma
and COPD
Phytomedicine is defined as a plant-based traditional
medical practice that uses various plant materials in mo-
dalities considered both preventive and therapeutic.
Herbs and plants naturally contain many active chemi-
cals and thus drugs derived from such sources can have
multiple health benefits when administered to patients.
Due to the presence of multiple active compounds in
phytomedicines they are an ideal candidate for treating
conditions with a variety of symptoms such as inflamma-
tory diseases which affect multiple systems.
Historically, particularly in Chinese and other Asian
cultures, plant-based medicines have been used to treat
and prevent lung disease, and to this day remain a major
therapeutic option; thus the idea of using plant-derived
medicines for treatment of asthma and COPD is not a
new concept. In fact some commonly used conventional
drugs are derived from plant and herbal extracts. Atro-
pine, a naturally occurring alkaloid extracted from
Atropa belladonna, acts on the parasympathetic nervous
system and has an antimuscarinic effect which inhibits
the contraction of smooth muscle tissue and reduces
mucus secretion. However, despite the anti-mucus se-
creting properties and smooth muscle relaxant effect, at-
ropine was found to be ineffective in improving the
symptoms of asthma in clinical trials [18]. Atropine re-
mains a mainstay of treatment of cardiac bradyarrhyth-
mias, and has been used successfully in the treatment of
conditions such as amblyopia, also known as lazy eye
[19]. While atropine itself was ineffective in treating
asthma in clinical trials a derivative of its active com-
pound has been adapted into the anticholinergic drug
ipratropium bromide which is used to treat broncho-
spasm which occurs during COPD and asthma [6, 5].
Over the years there has been considerable effort
undertaken to explore the efficacy and safety of plant-
based medicines and to elucidate the mechanisms
through which they might exert a therapeutic effect. In
the area of asthma and COPD therapies many promising
plant-based treatments have arisen from these studies. A
summarised version of the search results can be found
in Additional file 1: Table S1 and Table S2 for asthma
and COPD respectively. A summary of the compounds
mentioned and their beneficial effect can be found in
Additional file 1: Table S3.
For the purpose of this review we have selected a
number of these studies for further discussion to
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illustrate the potential of plant-based medicines for use
in the treatment and management of asthma and COPD.
Plant-derived therapies for asthma
A number of plant-based medicines have shown promising
results in clinical studies of asthma such as Anti-asthma
Herbal Medicine Intervention (ASHMI). ASHMI is a com-
bination of 3 extracts; Ling Zhi from Ganoderma lucidem,
Ku Shen from Sophora flavescentis and Gan Cao from Gly-
cyrhhiza uralensis, which has shown potential for the treat-
ment of asthma in both in vitro and in vivo (subsections i)
and ii) below respectively) models as well as in human pa-
tients. In vivo studies carried out by Zhang et al. [20] in
BALB/c mice sensitised with ovalbumin (OVA) and alum
showed that ASHMI abolished the early-phase airway
responses and prevented the late-phase airway hyper-
responsiveness. Their findings also suggested that
ASHMI directly affected airway narrowing through in-
hibition of acetylcholine-induced tracheal ring con-
striction ex vivo and increased production of the
smooth muscle relaxants prostacyclin and prostaglandin
I 2 (PGI2). ASHMI has also been shown to reduce lung
inflammation and mucus in an aged mouse model of
late-onset asthma [21].
i) Preclinical ASHMI studies: In vitro studies using a
human lung fibroblast cell line showed that Gan
Cao, one of the extracts used in ASHMI, decreased
secretion of interleukin (IL) 8, eotaxin 1 and stat 6
[22, 23] demonstrating the anti-inflammatory
property of this extract and a possible mechanism of
action in the treatment of asthma, particularly the
recently described subtype ‘neutrophilic asthma’
where severe asthma patients suffer from airway
neutrophilia (reviewed in [24]). Other in vitro
studies carried out in primary mouse cells
demonstrated a decrease in tumour necrosis factor
alpha (TNFα), nuclear factor kappa β (NFκB) and
brain derived neurotrophic factor (BDNF) levels
in cells pretreated with ASHMI in response to
lipopolysaccharide (LPS) [25], again emphasising
the anti-inflammatory properties of this
plant-based medicine.
ii) Clinical ASHMI studies: Clinical trials of ASHMI
have been undertaken in a 4-week double-blind,
randomised, trial carried out by Wen et al. [26]
comparing the effects of oral ASHMI, 4 capsules
(0.3 g/capsule) 3 times daily, with that of oral
prednisone, 20 mg once daily, in patients with
moderate to severe persistent asthma over a
period of 4 weeks. Both ASHMI and prednisone
significantly reduced symptoms and improved lung
function from baseline with prednisone group
showing significantly greater improvements in lung
function than the ASHMI group. Both compounds
exerted anti-inflammatory effects and no adverse
effects were reported during the short treatment
duration. While ASHMI displayed significantly less
improvements in lung function when compared to
prednisone it stilled displayed clinically relevant
reductions in patient symptom scores and
enhancements in lung function. Therefore
ASHMI can be considered a possible alternative
therapy for patients suffering with less severe
asthma as, unlike prednisone, there have
been no documented adverse side effects
reported during ASHMI therapy.
Another plant-based medicine used for the treatment
of asthma is Aleurites moluccana, a native tree of
Indonesia and India which has been used in traditional
remedies not only for the treatment of asthma but for
pain, fever and headaches [27–29]. More recently, the
anti-nociceptive effects of A. molluccana [30, 31] and its
mechanical anti-hypersensitivity properties [32] have
been investigated. A. mollucanna has also been found
to possess antiviral [33] and antimicrobial properties
[34] demonstrating how the presence of multiple ac-
tive compounds in plant extracts can have several
benefits to patients. Due to this historical link be-
tween A. mullucanna and anti-nociceptive and anti-
inflammatory therapies, A. mullucanna extracts have
been used to produce analgesic and anti-inflammatory
phytomedicines [35, 36]. The major focus of this work
was on the wound healing effects of A. mollucanna
extracts, although the use of this plant in traditional
remedies for asthma suggests that there is a possibil-
ity for the active compounds of A. mullucanna to be
adapted to produce a phytomedicine for asthma and
its related symptoms.
Nigella sativa, a plant native to South East Asia is
known for its relaxant effect on smooth muscle tissue
[37–39]. In addition, Boskabady and colleagues have
demonstrated that extracts and oils from N. sativa have
inhibitory effects on histamine (H1) receptors [40],
stimulatory effects on β-adrenergic receptors [41] and
anti-tussive effects [42]. To translate these promising
in vitro findings Boskabady and colleagues set out to in-
vestigate the effect of boiled N. sativa extract on lung
function in asthmatic patients [43]. In this study they
compared the bronchodilatory effects of N. sativa with
those of theophylline in 15 asthmatics. They found that
N. sativa did induce bronchodilation within 30 min of
administration but the magnitude was significantly less
than observed with theophylline and that both agents
were significantly less effective than the beta-2 agonist
salbutamol. Nonetheless they concluded that N. sativa
has relatively potent bronchodilatory effects but when
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given orally it is less effective than conventional bron-
chodilators. It is possible that the bronchodilatory effects
of compounds such as N. sativa could be enhanced if
formulated as inhaled therapy with delivery of the active
compounds directly to the airway.
Plant-based therapies for COPD
As mentioned above, COPD is characterised by airflow
obstruction that is fixed or only partially reversible and
which declines progressively over time. Treatments con-
sist of inhaled bronchodilators and corticosteroids either
as monotherapy or in combination and aim to decrease
symptom severity and improve QOL [6]. For some pa-
tients, treatment with roflumilast a phosphodiesertase-4
inhibitor has been shown to be effective although not
without adverse effects such as weight loss and nausea
[44]. Patients with COPD commonly have important co-
morbidities in particular cardiovascular, metabolic and
renal impairment. Therefore the safety profile of current
and novel therapies must be carefully scrutinised. Per-
haps of most interest recently has been the concern re-
garding the safety of inhaled corticosteroids especially at
high doses, with an increased rate of pneumonia having
been reported in a number of large clinical trials in pa-
tients with moderate to severe COPD who received
corticosteroid-containing inhaled therapy [16, 45, 46].
One approach to overcome this problem would be to
identify biomarkers to help identify those patients most
likely to benefit from inhaled corticosteroids and least
likely to suffer adverse effects. The discovery of novel
safe and effective therapies for COPD including those
derived from plant-based medicines represents an alter-
native and attractive solution. The following section re-
views some of the clinical trials of plant-based medicine
undertaken in the last 10 years in COPD patients. De-
tails of these trials have been summarised in Additional
file 1: Table S2. Reducing disease exacerbations and im-
proving quality of life (QOL) represent important treat-
ment goals in the management of COPD. A number of
clinical trials of herbal and plant-based treatments
for COPD have focused on these important treat-
ment outcomes. Li et al. [47] investigated the effect
in an open label study of the combination of three
different traditional Chinese plant-based medicines,
Bu-Fei Jian-Pi, Bu-Fei Yi-Shen and Yi-Qi Zi-Shen,
formulated as granules and given as add-on therapies
to conventional Western medicine on symptoms and
QOL in COPD patients. They found that compared
to conventional therapy the addition of the plant-based
medicine combination was associated with improved
symptom scores (cough, sputum, chest tightness, and
breathlessness) and improvement in QOL scores across
the physical, psychological, environmental and social
domains.
A number of clinical trials have investigated the
effect of plant-based medicine on lung function and
their potential anti-inflammatory effect on systemic
circulation. Liu et al. [48] studied the effects of the
Yiqibushenhuoxue, a complex mixture of herbs used
in traditional Chinese medicine believed to relieve re-
spiratory symptoms such as cough and shortness of
breath as well as improve kidney and splenic func-
tion, as a complementary therapy for COPD. The
study was designed as a 12-week open label compari-
son of the plant-based mixture and a fixed dose com-
bination ICS/LABA therapy compared to the ICS/
LABA alone in patients with stable COPD. Study
endpoints were QOL measured using the St George’s
Respiratory Questionnaire (SGRQ) and lung function
(% predicted FEV1 and FEV1/FVC). When compared
to those in the control group, participants allocated
to the plant-based treatment group had similar im-
provements in lung function but reported significantly
greater improvements in SGRQ scores. Based on these
findings, the authors proposed larger and longer studies
to determine the optimal effect of Yiqibushenhuoxue in
patients with COPD. Whilst this particular study re-
ported no improvements in lung function when the
plant-based medicine was added to conventional
COPD treatment other researchers have seen marked
improvement in lung function following the use of a
plant-based medicine. Guo et al. [49] conducted a
randomised, double-blinded, placebo-controlled study
investigating the effects of Bu-Fei granules on the
frequency of COPD exacerbations along with lung
function and serum inflammatory mediator levels. Bu-
Fei granules have been historically used in traditional
Chinese medicine to enhance lung immune functions.
In this study patients were not permitted to use any
other form of COPD medication whilst receiving Bu-Fei
granules. The authors observed a significant reduction
in symptom scores in the treatment group when com-
pared to the control group and they also saw an im-
provement in FEV1, FVC, FEV/FVC and PEF in the
treatment group which did not occur in the patients
receiving placebo. When inflammatory mediator levels
were measured they found that the levels of IL8,
TNFα and transforming growth factor beta (TGFβ)
were all reduced in patient serum samples from the
treatment group with no major changes occurring in
those of the control group. These results show that
Bu-Fei granules alleviate the symptoms of COPD,
may help delay the deterioration of lung function in
patients and also have an anti-inflammatory effect. In
this study they also carried out a follow up examin-
ation 6 and 12 months after the trial ended and
found that the patients of the treatment group experi-
enced significantly fewer exacerbations than the
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patients of the control group suggesting that Bu-Fei
granules may have a long-lasting benefit over conven-
tional medication.
Conclusion
The current approach to managing both asthma and
COPD is predominately based on the use of inhaled
bronchodilators and corticosteroids. For a large number
of patients these treatments are effective at improving
lung function and quality of life and reducing symptoms
and disease exacerbations. However, concerns exist re-
garding the adverse effects of these treatments in some
patients especially when used in high dose. Furthermore
there is growing recognition of subgroups of patients
that appear refractory to current therapy and who are
considered ‘difficult to treat’. At present, novel and ex-
pensive biologic therapies are being developed to address
this unmet need. Alternative approaches to address
the issue of adverse effects and reduced efficacy in-
clude the use of phytomedicines. However progress in
this area is hampered by a lack of compelling evi-
dence. Therefore there is a need for properly con-
ducted scientific research into the effects of safe,
plant-based medicines in asthma and COPD. Of the
articles included in this review the vast majority were
carried out as randomised, double-blind, placebo-
controlled trials which shows that an increasing num-
ber of research groups are beginning to consider
plant-based medicines as serious therapies for diseases
rather than as homeopathic or holistic remedies,
which has been the traditional opinion of most of the
modern world. Along with this change in attitude, these
studies have generally yielded positive results in patients
following the addition of a plant-based therapy which
emphasises the possibility of developing medical treat-
ments for inflammatory diseases which are both effica-
cious and have minimal adverse side effects as most
clinical trials mentioned here did not report any side ef-
fects following the use of plant-based medicines. If any
side effects were observed they were generally mild and
were spontaneously rectified i.e. no further medical in-
terventions were needed [50]. Whilst the majority of the
publications mentioned here.
Along with studying the clinical efficacy of these nat-
ural compounds it is also important for us to understand
the mechanisms through which these compounds exert
their effect. While the mechanisms of some promising
phytomedicines, such as ASHMI, have begun to be elu-
cidated (reviewed in [51]) the mechanisms of most
plant-based medicines remain unknown. There is an in-
creasing willingness within the scientific and medical
community to explore the role of phytomedicines for
the treatment and management of asthma and COPD.
It is, however, important that research and drug
development in this area is conducted with integrity and
with the same rigorous standards of safety and efficacy
as mandated for the development of any novel “conven-
tional” therapy.
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